Is this the first partial epigenetic reprogramming therapy for the brain?

YouthBio receives positive FDA feedback on therapy designed to restore youthful gene expression patterns and address drivers of Alzheimer’s. Epigenetic rejuvenation startup YouthBio Therapeutics has received encouraging feedback from the US FDA on its investigational Alzheimer’s therapy YB002 as it seeks to bring partial cellular reprogramming into the clinic. The company today revealed that, following […] The post Is this the first partial epigenetic reprogramming therapy for the brain? appeared first on Longevity.Technology.